[SCHEDULE 13G/A] Shuttle Pharmaceuticals Holdings, Inc. SEC Filing
Armistice Capital, LLC and Steven Boyd filed an amended Schedule 13G reporting shared beneficial ownership of 56,237 shares of Shuttle Pharmaceuticals Holdings, Inc. common stock, representing 4.99% of the class. Armistice Capital is the investment manager of Armistice Capital Master Fund Ltd., the direct holder of the shares, and pursuant to an investment management agreement exercises voting and investment power over those securities. Mr. Boyd, as managing member of Armistice Capital, is reported with the same shared voting and dispositive power. The filing states the position is held in the ordinary course of business and not for the purpose of changing or influencing control.
Armistice Capital, LLC e Steven Boyd hanno presentato un emendamento al Schedule 13G segnalando la titolarit脿 condivisa di 56.237 azioni ordinarie di Shuttle Pharmaceuticals Holdings, Inc., corrispondenti al 4,99% della categoria. Armistice Capital agisce come gestore degli investimenti per Armistice Capital Master Fund Ltd., detentore diretto delle azioni, e in virt霉 di un accordo di gestione esercita il diritto di voto e il potere di investimento su tali titoli. Il sig. Boyd, in qualit脿 di membro amministratore di Armistice Capital, 猫 indicato con gli stessi poteri condivisi di voto e di disposizione. Nell'atto si specifica che la posizione 猫 detenuta nell'ordinaria attivit脿 aziendale e non con l'intento di modificare o influenzare il controllo.
Armistice Capital, LLC y Steven Boyd presentaron una enmienda al Schedule 13G informando la titularidad compartida de 56.237 acciones ordinarias de Shuttle Pharmaceuticals Holdings, Inc., que representan el 4,99% de la clase. Armistice Capital es el gestor de inversiones de Armistice Capital Master Fund Ltd., titular directo de las acciones, y conforme a un contrato de gesti贸n de inversiones ejerce el derecho de voto y el poder de inversi贸n sobre dichos valores. El Sr. Boyd, como miembro gerente de Armistice Capital, figura con los mismos poderes compartidos de voto y disposici贸n. La presentaci贸n indica que la posici贸n se mantiene en el curso ordinario del negocio y no con el prop贸sito de cambiar o influir en el control.
Armistice Capital, LLC鞕� Steven Boyd電� 靾橃爼霅� Schedule 13G毳� 鞝滌稖頃橃棳 Shuttle Pharmaceuticals Holdings, Inc. 氤错喌欤� 56,237欤�(頃措嫻 欤检嫕 韥措灅鞀れ潣 4.99%)鞐� 雽�頃� 瓿惦彊 鞁れ唽鞙犼秾鞚� 氤搓碃頄堨姷雼堧嫟. Armistice Capital鞚� 頃措嫻 欤检嫕鞚� 歆侅爲 氤挫湢鞛愳澑 Armistice Capital Master Fund Ltd.鞚� 韴瀽 甏�毽瀽鞚措┌, 韴瀽甏�毽硠鞎届棎 霐半澕 頃措嫻 歃濌秾鞐� 雽�頃� 鞚橁舶甓� 氚� 韴瀽甓岇潉 頄夓偓頃╇媹雼�. Boyd 鞌姅 Armistice Capital鞚� 甏�毽� 氅る矂搿滌劀 霃欖澕頃� 瓿惦彊 鞚橁舶甓� 氚� 觳橂秳甓岇潉 氤挫湢頃� 鞛愲 氤搓碃霅橃棃鞀惦媹雼�. 鞝滌稖 靹滊鞐愲姅 頃措嫻 歆�攵勳澊 韱奠儊鞝侅澑 鞓侅梾 瓿检爼鞐愳劀 氤挫湢霅橁碃 鞛堨溂氅� 歆�氚瓣秾鞚� 氤�瓴巾晿瓯半倶 鞓來枼鞚� 氙胳範 氇╈爜鞚� 鞎勲嫎鞚� 氇呾嫓霅橃柎 鞛堨姷雼堧嫟.
Armistice Capital, LLC et Steven Boyd ont d茅pos茅 un Schedule 13G amend茅 d茅clarant la propri茅t茅 b茅n茅ficiaire conjointe de 56听237 actions ordinaires de Shuttle Pharmaceuticals Holdings, Inc., repr茅sentant 4,99% de la cat茅gorie. Armistice Capital est le gestionnaire d'investissement de Armistice Capital Master Fund Ltd., d茅tenteur direct des actions, et exerce, en vertu d'un contrat de gestion d'investissement, le pouvoir de vote et d'investissement sur ces titres. M. Boyd, en tant que membre dirigeant d'Armistice Capital, est d茅clar茅 avec les m锚mes pouvoirs partag茅s de vote et de disposition. Le d茅p么t indique que la position est d茅tenue dans le cours normal des affaires et n'a pas pour but de modifier ou d'influencer le contr么le.
Armistice Capital, LLC und Steven Boyd reichten eine ge盲nderte Schedule 13G ein und meldeten damit das gemeinsame wirtschaftliche Eigentum an 56.237 Aktien der Stammaktien von Shuttle Pharmaceuticals Holdings, Inc., was 4,99% der Klasse entspricht. Armistice Capital ist Investmentmanager des direkte Anteilseigners Armistice Capital Master Fund Ltd. und 眉bt aufgrund eines Investmentmanagementvertrags Stimm- und Anlagebefugnis 眉ber diese Wertpapiere aus. Herr Boyd wird als gesch盲ftsf眉hrendes Mitglied von Armistice Capital mit denselben gemeinsamen Stimm- und Verf眉gungsbefugnissen angegeben. In der Einreichung wird angegeben, dass die Position im normalen Gesch盲ftsverlauf gehalten wird und nicht dazu dient, die Kontrolle zu 盲ndern oder zu beeinflussen.
- Clear regulatory disclosure of beneficial ownership by Armistice Capital and Steven Boyd
- Position documented as held in ordinary course, not for control purposes
- Identification of investment manager relationship (Armistice Capital manages the Master Fund holding the shares)
- Stake remains below 5% (4.99%), limiting potential influence and materiality
- No indication of increased activism or intent to change control, so limited near-term corporate impact
Insights
TL;DR: Disclosure shows a sub-5% passive stake managed by Armistice Capital with shared voting power, a routine institutional filing.
The Schedule 13G/A reports a 4.99% holding (56,237 shares) by Armistice Capital and Steven Boyd, indicating ownership remains below the 5% threshold that typically triggers stricter reporting and activism concerns. The filing clarifies that Armistice Capital acts as investment manager to the Master Fund, exercising voting and dispositive power under an Investment Management Agreement. The certification states the position is held in the ordinary course of business and not to influence control, which aligns with passive investor treatment under the rules. For investors, this is a transparent disclosure of a modest institutional position rather than a control or activist event.
TL;DR: Governance impact is limited: shared voting power exists but reported ownership is below action thresholds.
The filing identifies shared voting and dispositive power rather than sole control, and expressly disclaims acquisition for control purposes. Because the reported stake is 4.99%, it does not meet common materiality triggers for significant influence or mandatory Schedule 13D-level disclosures. The joint filing statement documents that Armistice Capital and Steven Boyd file jointly and accept responsibility for timely amendments. This is standard governance practice for an investment manager and its principal when the manager controls investment decisions for a third-party fund.
Armistice Capital, LLC e Steven Boyd hanno presentato un emendamento al Schedule 13G segnalando la titolarit脿 condivisa di 56.237 azioni ordinarie di Shuttle Pharmaceuticals Holdings, Inc., corrispondenti al 4,99% della categoria. Armistice Capital agisce come gestore degli investimenti per Armistice Capital Master Fund Ltd., detentore diretto delle azioni, e in virt霉 di un accordo di gestione esercita il diritto di voto e il potere di investimento su tali titoli. Il sig. Boyd, in qualit脿 di membro amministratore di Armistice Capital, 猫 indicato con gli stessi poteri condivisi di voto e di disposizione. Nell'atto si specifica che la posizione 猫 detenuta nell'ordinaria attivit脿 aziendale e non con l'intento di modificare o influenzare il controllo.
Armistice Capital, LLC y Steven Boyd presentaron una enmienda al Schedule 13G informando la titularidad compartida de 56.237 acciones ordinarias de Shuttle Pharmaceuticals Holdings, Inc., que representan el 4,99% de la clase. Armistice Capital es el gestor de inversiones de Armistice Capital Master Fund Ltd., titular directo de las acciones, y conforme a un contrato de gesti贸n de inversiones ejerce el derecho de voto y el poder de inversi贸n sobre dichos valores. El Sr. Boyd, como miembro gerente de Armistice Capital, figura con los mismos poderes compartidos de voto y disposici贸n. La presentaci贸n indica que la posici贸n se mantiene en el curso ordinario del negocio y no con el prop贸sito de cambiar o influir en el control.
Armistice Capital, LLC鞕� Steven Boyd電� 靾橃爼霅� Schedule 13G毳� 鞝滌稖頃橃棳 Shuttle Pharmaceuticals Holdings, Inc. 氤错喌欤� 56,237欤�(頃措嫻 欤检嫕 韥措灅鞀れ潣 4.99%)鞐� 雽�頃� 瓿惦彊 鞁れ唽鞙犼秾鞚� 氤搓碃頄堨姷雼堧嫟. Armistice Capital鞚� 頃措嫻 欤检嫕鞚� 歆侅爲 氤挫湢鞛愳澑 Armistice Capital Master Fund Ltd.鞚� 韴瀽 甏�毽瀽鞚措┌, 韴瀽甏�毽硠鞎届棎 霐半澕 頃措嫻 歃濌秾鞐� 雽�頃� 鞚橁舶甓� 氚� 韴瀽甓岇潉 頄夓偓頃╇媹雼�. Boyd 鞌姅 Armistice Capital鞚� 甏�毽� 氅る矂搿滌劀 霃欖澕頃� 瓿惦彊 鞚橁舶甓� 氚� 觳橂秳甓岇潉 氤挫湢頃� 鞛愲 氤搓碃霅橃棃鞀惦媹雼�. 鞝滌稖 靹滊鞐愲姅 頃措嫻 歆�攵勳澊 韱奠儊鞝侅澑 鞓侅梾 瓿检爼鞐愳劀 氤挫湢霅橁碃 鞛堨溂氅� 歆�氚瓣秾鞚� 氤�瓴巾晿瓯半倶 鞓來枼鞚� 氙胳範 氇╈爜鞚� 鞎勲嫎鞚� 氇呾嫓霅橃柎 鞛堨姷雼堧嫟.
Armistice Capital, LLC et Steven Boyd ont d茅pos茅 un Schedule 13G amend茅 d茅clarant la propri茅t茅 b茅n茅ficiaire conjointe de 56听237 actions ordinaires de Shuttle Pharmaceuticals Holdings, Inc., repr茅sentant 4,99% de la cat茅gorie. Armistice Capital est le gestionnaire d'investissement de Armistice Capital Master Fund Ltd., d茅tenteur direct des actions, et exerce, en vertu d'un contrat de gestion d'investissement, le pouvoir de vote et d'investissement sur ces titres. M. Boyd, en tant que membre dirigeant d'Armistice Capital, est d茅clar茅 avec les m锚mes pouvoirs partag茅s de vote et de disposition. Le d茅p么t indique que la position est d茅tenue dans le cours normal des affaires et n'a pas pour but de modifier ou d'influencer le contr么le.
Armistice Capital, LLC und Steven Boyd reichten eine ge盲nderte Schedule 13G ein und meldeten damit das gemeinsame wirtschaftliche Eigentum an 56.237 Aktien der Stammaktien von Shuttle Pharmaceuticals Holdings, Inc., was 4,99% der Klasse entspricht. Armistice Capital ist Investmentmanager des direkte Anteilseigners Armistice Capital Master Fund Ltd. und 眉bt aufgrund eines Investmentmanagementvertrags Stimm- und Anlagebefugnis 眉ber diese Wertpapiere aus. Herr Boyd wird als gesch盲ftsf眉hrendes Mitglied von Armistice Capital mit denselben gemeinsamen Stimm- und Verf眉gungsbefugnissen angegeben. In der Einreichung wird angegeben, dass die Position im normalen Gesch盲ftsverlauf gehalten wird und nicht dazu dient, die Kontrolle zu 盲ndern oder zu beeinflussen.
FAQ
What percentage of SHPH does Armistice Capital report owning?
Who specifically filed the Schedule 13G/A for SHPH?
Does the filing indicate Armistice Capital intends to influence control of SHPH?
How does Armistice Capital hold the reported SHPH shares?
When was the Schedule 13G/A signed?
